On Thursday, Precision BioSciences Inc.’s DTIL companion iECURE reported scientific efficacy and security knowledge within the first affected person dosed with ECUR-506 within the Section 1/2 OTC-HOPE research.
ECUR-506 is iECURE’s in vivo gene insertion program designed to deal with neonatal-onset Ornithine Transcarbamylase (OTC) deficiency. It makes use of a PCSK9-specific ARCUS nuclease, licensed from Precision, that allows the insertion of a purposeful copy of the OTC gene.
Ornithine transcarbamylase deficiency is a uncommon genetic situation that causes ammonia to construct up within the blood. The situation is extra frequent in boys than women and tends to be extra extreme when signs emerge shortly after delivery.
Therapy with ECUR-506 was usually properly tolerated in first toddler dosed with no vital scientific security issues aside from asymptomatic transaminitis at 4 weeks.
BMO Capital Markets upgraded Precision BioSciences, “Acknowledging the N=1, iECURE knowledge seem very promising, offering early scientific validation for ARCUS.”
Analyst Kostas Biliouris writes that early ECUR-506 efficacy gives preliminary scientific derisking of in vivo ARCUS efficacy/modifying platform.
In November, Precision BioSciences shared preclinical knowledge for the PBGENE-HBV program that strengthened the security profile and potential to ship a purposeful treatment for continual hepatitis B, supporting development into first-in-human scientific research.
The corporate is conducting ELIMINATE-B Section 1 trial. ELIMINATE-B is open and at present screening and accruing sufferers, and Precision expects to report knowledge from the research because it matures all through 2025.
BMO Capital analyst writes that the HBV readout in 2025 may drive a 100-200%+ inventory upside.
On Thursday, BMO upgraded from Market Carry out to Outperform with a value goal of $34 based mostly on ECUR-506 preliminary scientific derisking of in vivo ARCUS modifying and a proprietary gene modifying platform with a differentiated mechanism and probably aggressive.
Worth Motion: DTIL inventory is up 25.8% at $5.66 eventually examine Friday.
Learn Subsequent:
Picture through Shutterstock.
Market Information and Information delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
